gsk_boronia_australia

GlaxoSmithKline opens new £56 million facility in Hertfordshire

pharmafile | April 19, 2016 | News story | Manufacturing and Production |  Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware 

GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England.

The facility in Ware will create 150 new jobs and will form the new base for the pharma giant’s production of inhalers to use with respiratory medicines. Chief executive of GSK, Sir Andrew Witty, and life sciences minister, George Freeman MP, were given a tour of the facility which produces the Ellipta inhalers.

This is the latest investment in the Ware facility which formed part of a £200 million investment by GSK into its UK facilities.

Advertisement

Witty says: “This new facility demonstrates our commitment to manufacturing in the UK which continues to be a very positive environment for life sciences investment. We currently export Ellipta inhalers from Ware to over 74 countries and the new facility opened today will increase capacity to meet growing demand for our new portfolio of respiratory medicines worldwide.”

Freeman added: “This £56 million investment by GSK is fantastic news for Ware and the UK’s thriving life sciences industry.”

Sean Murray

Related Content

Brenntag and dsm-firmenich expand biopharma vitamin partnership

Brenntag Pharma and dsm-firmenich have entered a long-term global distribution partnership covering GMP-grade vitamins for …

BioDuro establishes joint manufacturing venture with Cenra

BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

The Gateway to Local Adoption Series

Latest content




Five Facts about COPD

October 11, 2026